Roberts J A, Rodger I W, Thomson N C
Thorax. 1985 Apr;40(4):261-7. doi: 10.1136/thx.40.4.261.
Airway responsiveness to histamine in man may be determined by the smooth muscle sensitivity to histamine or to the interaction between vagal nerve input and smooth muscle sensitivity. We have compared in vivo responsiveness to histamine with in vitro smooth muscle sensitivity to histamine in 20 non-asthmatic patients and one asthmatic patient undergoing thoracic surgery. Histamine responsiveness was assessed in the first 10 non-asthmatics without atropine pretreatment, in the second 10 after atropine pretreatment, and in the asthmatic patient both with and without atropine. In vivo responsiveness was also measured in 10 normal subjects and 10 asthmatic patients not undergoing surgery. Results were expressed as the provocation concentration (PC) causing a decrease in FEV1 of 20% (PC20FEV1) and in specific airways conductance of 35% (PC35SGaw), and in terms of maximal expiratory flow at 35% vital capacity, measured from the partial (V35(P] and complete (V35(C] flow volume curves of 35% (PC35V35(P); PC35V35(C]. In vitro smooth muscle sensitivity to histamine of bronchial tissue obtained at thoracotomy was expressed as the concentration causing a 50% maximum contraction (EC50) and as the maximum tension generated. There was considerable variation between patients in the in vivo responsiveness but a relatively narrow range for in vitro responses. There was no significant correlation between in vivo responsiveness, either with or without atropine pretreatment, and in vitro results. The asthmatic patient showed hyperresponsiveness in vivo but but not in vitro. These results suggest that in vitro airway smooth muscle sensitivity to histamine is not the sole determinant of in vivo airway responsiveness and that this lack of relationship is not explained by the influence of vagal nerve input on in vivo measurements. The results in the asthmatic patient suggest that airway hyperresponsiveness may be an in vivo phenomenon which is not related to a primary abnormality of airway smooth muscle.
人类气道对组胺的反应性可能由平滑肌对组胺的敏感性或迷走神经输入与平滑肌敏感性之间的相互作用决定。我们比较了20名非哮喘患者和1名接受胸外科手术的哮喘患者体内对组胺的反应性与体外支气管平滑肌对组胺的敏感性。对前10名未用阿托品预处理的非哮喘患者、后10名用阿托品预处理的非哮喘患者以及该哮喘患者在使用和未使用阿托品的情况下评估组胺反应性。还对10名正常受试者和10名未接受手术的哮喘患者测量了体内反应性。结果以引起第一秒用力呼气容积(FEV1)下降20%的激发浓度(PC)、引起气道比传导率下降35%的激发浓度(PC35SGaw)以及根据35%肺活量时的最大呼气流量来表示,该最大呼气流量从35%(PC35V35(P);PC35V35(C))的部分(V35(P))和完整(V35(C))流量-容积曲线测量得出。开胸手术时获取的支气管组织对组胺的体外平滑肌敏感性以引起最大收缩50%的浓度(EC50)和产生的最大张力来表示。患者之间的体内反应性存在相当大的差异,但体外反应的范围相对较窄。无论是否进行阿托品预处理,体内反应性与体外结果之间均无显著相关性。该哮喘患者在体内表现出高反应性,但在体外未表现出高反应性。这些结果表明,体外气道平滑肌对组胺的敏感性不是体内气道反应性的唯一决定因素,并且这种缺乏相关性不能用迷走神经输入对体内测量的影响来解释。该哮喘患者的结果表明,气道高反应性可能是一种体内现象,与气道平滑肌的原发性异常无关。